Progress in Understanding Ferroptosis and Challenges in Its Targeting for Therapeutic Benefit
- PMID: 32302583
- PMCID: PMC7346472
- DOI: 10.1016/j.chembiol.2020.03.015
Progress in Understanding Ferroptosis and Challenges in Its Targeting for Therapeutic Benefit
Abstract
Ferroptosis is an iron-dependent cell-death modality driven by oxidative phospholipid damage. In contrast to apoptosis, which enables organisms to eliminate targeted cells purposefully at specific times, ferroptosis appears to be a vulnerability of cells that otherwise use high levels of polyunsaturated lipids to their advantage. Cells in this high polyunsaturated lipid state generally have safeguards that mitigate ferroptotic risk. Since its recognition, ferroptosis has been implicated in degenerative diseases in tissues including kidney and brain, and is a targetable vulnerability in multiple cancers-each likely characterized by the high polyunsaturated lipid state with insufficient or overwhelmed ferroptotic safeguards. In this Perspective, we present progress toward defining the essential roles and key mediators of lipid peroxidation and ferroptosis in disease contexts. Moreover, we discuss gaps in our understanding of ferroptosis and list key challenges that have thus far limited the full potential of targeting ferroptosis for improving human health.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Interests S.L.S. serves on the Board of Directors of the Genomics Institute of the Novartis Research Foundation (“GNF”); is a shareholder and serves on the Board of Directors of Jnana Therapeutics; is a shareholder of Forma Therapeutics; is a shareholder and advises Kojin Therapeutics, Kisbee Therapeutics, Decibel Therapeutics, and Eikonizo Therapeutics; serves on the Scientific Advisory Boards of Eisai Co., Ltd., Ono Pharma Foundation, Exo Therapeutics, and F-Prime Capital Partners; and is a Novartis Faculty Scholar. Kojin Therapeutics in particular explores the medical potential of cell plasticity related to ferroptosis. Y.Z. declares no conflict of interest related to this work.
Figures
References
-
- Achitei D, Ciobica A, Balan G, Gologan E, Stanciu C, and Stefanescu G (2013). Different profile of peripheral antioxidant enzymes and lipid peroxidation in active and non-active inflammatory bowel disease patients. Dig. Dis. Sci 58, 1244–1249. - PubMed
-
- Alim I, Caulfield JT, Chen Y, Swarup V, Geschwind DH, Ivanova E, Seravalli J, Ai Y, Sansing LH, Ste Marie EJ, et al. (2019). Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke. Cell 177, 1262–1279.e25. - PubMed
-
- Badgley MA, Kremer D, Carlo Maurer H, DelGiorno KE, Lee H-J, Purohit V, Sagalovskiy I, Ma A, Kapillian J, Firl CEM, et al. (2019). “Induction of pancreatic tumor-selective ferroptosis through modulation of cystine import.”
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
